3 Dr. Reddy’s Inspection Observations

FDA has released the FDA-483 issued following a 9/11-9/15 inspection at the Dr. Reddy’s drug manufacturing facility in Mirfield, West Yorkshire, UK. The specific observations cited were: 

  •          procedures are not established or followed;
  •          cleaning procedures or clean status is not established; and
  •          manually managed materials in the warehouse are not separated during storage.

 

Read more